PREDICT™

AI-enhanced, game-changing device designed to enable early prediction of heart failure — non-invasive, accurate, and effortless to use.

KardioVis PREDICT™ is a PATENT-pending, non-invasive technology being developed to support early prediction of heart failure and empower more proactive patient management. It aims to provide timely clinical insights to reduce hospitalizations, manage healthcare costs, and improve patient outcomes.

The device is currently under development toward MDR Class IIa certification and FDA clearance, and is designed to non-invasively detect early indicators of heart failure up to four weeks before clinical onset.

An end-to-end solution delivering reliable alerts to physicians (when enabled), unlocking effortless and scalable patient monitoring.

A person resting on a beige couch with hands clasped, wearing a blue sweater and brown pants, with a Kardiovis device (called PREDICT) on their chest.

A middle-aged man with gray hair and a beard, smiling and looking at his smartphone in a living room with a large window overlooking the ocean.

What Makes It Unique (Patent Pending)

Unlike implantable monitors or skin patches, PREDICT™ is being developed to offer the clinical insight and signal quality typically associated with invasive solutions, while providing exceptional comfort, accessibility, and unmatched 10-second measurement speed.

Heart failure affects more than 50 million people worldwide. PREDICT™ aims to give healthcare systems a way to support earlier intervention, potentially reducing readmissions, lowering costs, and improving patient outcomes. KardioVis represents a shift toward proactively identifying early signs of deterioration, enabling prediction before symptoms begin.

KardioVis PREDICT™ is designed to measures key cardiac signals without using indirect estimations.

The scientific background

KardioVis PREDICT™ combines advanced electromechanical sensing with artificial intelligence to analyze early cardiac patterns that conventional monitoring tools may not capture. In a 10-second test, the patient simply places the compact device on the chest — no skin contact, patches, or electrodes required.

A diagram with a central circle labeled 'Scientific Background.' Four quadrants extend from it, each with a title, icon, and text. The top left quadrant is titled 'Third Heart Sound' with hearts icon, stating it's an early sign of heart failure. The top right is labeled 'Fourth Heart Sound' with heart and ECG icon, indicating a marker of ventricular stiffness and diastolic dysfunction. The bottom left shows a stopwatch icon and discusses cardiac time intervals' role in risk stratification of heart failure. The bottom right has a fast arrow icon, concerning cardiac vibrations, and states they provide reliable information for all heart sounds and cardiac intervals.

The system measures and analyzes first, second, third, and fourth heart sounds (S1, S2, S3, S4), as well as cardiac time intervals. A 3-derivation ECG can also be captured as an optional feature for hospital and clinic settings. These parameters are processed using proprietary signal-fusion and deep-learning algorithms designed to identify early patterns associated with cardiac decompensation.

The system generates a predictive, AI-enhanced risk indicator that can be transmitted securely to physicians via a connected digital platform, supporting more proactive patient management.

Key features include: Portable, 10-second measurement suitable for hospital, clinic, or home environments.